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Abstract
Background: Cytokines and cytokine receptor concentrations increase in plasma and cerebrospinal fluid (CSF) of
patients following subarachnoid haemorrhage (SAH). The relationship between plasma and CSF cytokines,
and factors affecting this, are not clear.
Methods: To help define the relationship, paired plasma and cerebrospinal fluid (CSF) samples were collected from
patients subject to ventriculostomy. Concentrations of key inflammatory cytokines, interleukin (IL)-1ß, IL-1 receptor
antagonist (IL-1Ra), IL-1 receptor 2, IL-6, IL-8, IL-10, tumour necrosis factor (TNF)-α, and TNF receptors (TNF-R) 1 and
2 were determined by immunoassay of CSF and plasma from 21 patients, where samples were available at three or
more time points.
Results: Plasma concentrations of IL-1ß, IL-1Ra, IL-10, TNF-α and TNF-R1 were similar to those in CSF. Plasma
TNF-R2 and IL-1R2 concentrations were higher than in CSF. Concentrations of IL-8 and IL-6 in CSF were
approximately10 to 1,000-fold higher than in plasma. There was a weak correlation between CSF and plasma IL-8
concentrations (r = 0.26), but no correlation for IL-6. Differences between the central and peripheral pattern of IL-6
were associated with episodes of ventriculostomy-related infection (VRI). A VRI was associated with CSF IL-6
>10,000 pg/mL (P = 0.0002), although peripheral infection was not significantly associated with plasma IL-6.
Conclusions: These data suggest that plasma cytokine concentrations cannot be used to identify relative changes
in the CSF, but that measurement of CSF IL-6 could provide a useful marker of VRI.
Keywords: Cerebrospinal fluid, Cytokines, Infection, Interleukin-6, Markers, Plasma, Subarachnoid haemorrhage,
Ventriculostomy
Background
Experimental and clinical studies of traumatic brain in-
jury and stroke have identified inflammation as an im-
portant element of the pathological response [1,2]. In
clinical studies, the relationship between clinical status
and inflammation has commonly been established by
measuring inflammatory markers in plasma or cerebro-
spinal fluid (CSF) [3-6]. Collection of CSF is rarely indi-
cated clinically in conditions such as ischaemic stroke,
but is possible in patients with traumatic injury or sub-
arachnoid haemorrhage (SAH), where CSF from the lat-
eral ventricles can be sampled over time in those who,
for clinical reasons, have had an external ventricular
drain (EVD) inserted. In a number of clinical studies of
both stroke and SAH, inflammation within the CNS has
been imputed by detection of increased inflammatory
markers in plasma. Support for the validity of this
derives from clinical studies that have described an asso-
ciation between plasma inflammatory markers and out-
come [7-9]. The relationship between inflammatory
markers in CSF and plasma is, however, uncertain. Do
the increased plasma markers originate primarily in the
brain or are they generated peripherally? Could it be that
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plasma markers identify systemic inflammation, or in-
flammation at the vascular interface, as an important de-
terminant of outcome, relative to inflammation apparent
from CSF data? Addressing these questions has import-
ant mechanistic implications in terms of understanding
the relative importance of central and peripheral inflam-
mation in these conditions.
The primary objective here was therefore to define the
relationship between central and peripheral markers of
inflammation, following SAH. To achieve this we under-
took a prospective study to compare peripheral (plasma)
and central (CSF) inflammatory markers in patients with
SAH. This was conducted as part of a larger study of
delayed cerebral ischaemia in patients with SAH [10]
and took advantage of the availability of CSF from
patients who had EVDs placed as part of their clinical
care. Patients with EVDs are often critically ill and at
high risk of infections. Since infection is also a potent in-
flammatory stimulus, a secondary, retrospective analysis
was undertaken to examine the extent to which periph-
eral infection or ventriculostomy-related infection (VRI)
was associated with observed changes in peripheral or
central IL-6.
Methods
Patient inclusion criteria and data collection
Patients with SAH were eligible for this study if they
presented within 7 days of symptom onset to the
Greater Manchester Neuroscience Centre at Salford
Royal NHS Foundation Trust and required placement of
an external ventricular drain (EVD). All but three
patients were recruited consecutively from a cohort that
is reported in detail elsewhere [10]. After this, three add-
itional patients were recruited consecutively, under the
same conditions, since we had a target of at least 20
patients. Four patients only were excluded, on the basis
that less than three paired blood and CSF samples were
collected. Prior ethical approval was obtained from the
Bolton research Ethics Committee, via the National Re-
search Ethics Service, and the University of Manchester
Research Ethics Committee. Informed consent was
obtained from each patient or their representative.
Adult patients (>18 years) with a confirmed diagnosis
of SAH (CT imaging or positive xanthochromia) were
identified between January 2004 and June 2006. Eligibil-
ity was restricted to those with an underlying aneurysm
who underwent formal angiography.
A detailed record of clinical presentation was made.
This included presenting features, modified Rankin score,
World Federation of Neurosurgeons Scale (WFNS), Fisher
grade, Glasgow coma score aneurysm size and location,
detailed demographics, infection and medication screen,
atherosclerotic risk factors and physiological parameters.
Daily clinical assessments included changes in medication,
GCS, temperature, pulse rate, white cell count (WCC) and
other evidence of infection.
A 2 mL CSF sample was collected at time of EVD in-
sertion, where possible, and a concurrent 10 mL sample
of blood was collected into 100 units of pyrogen-free
heparin. Samples were cooled to 4°C and centrifuged for
15 min at 2,000 g. Plasma and CSF were decanted and
stored at −70°C, prior to analysis of inflammatory mar-
kers. Clinical assessments were continued on a daily
basis and further paired CSF and plasma samples were
collected between 07:00 and 11:00, until 7 days after
EVD insertion, where possible.
Infection status
Infection status was determined from retrospective ana-
lysis of patient records, including the infection screening
and antibiotic records on the study clinical report form.
Definition of infection was divided into: (1) Definite: for
peripheral infection this required positive culture, plus
clinical picture of infection, raised WCC or commence-
ment of antibiotics, while for VRI a positive culture with
a clinical picture of infection or commencement of
intrathecal antibiotics was necessary; (2) Probable: for
peripheral infection this was positive culture in the ab-
sence of clinical picture or raised WCC/ CRP, but where
antibiotics were not started; or negative culture in the
presence of a clinical picture of infection or raised
WCC/CRP, where antibiotics were not started. For VRI
this was raised CSF WCC: red cell count ratio (>1:700),
in the absence of positive culture or starting intrathecal
antibiotics, but with a clinical picture of infection; (3)
Unlikely: very limited documentation suggesting infec-
tion; and (4) No infection: no documentation suggesting
infection, or documentation that excluded infection.
Only those infections that were present at study entry,
diagnosed during collection of samples, or diagnosed up
to 2 days post sampling were counted as relevant.
Cytokine assays
Measurement of interleukin-1ß (IL-1ß), sIL-1R2, TNF-α,
sTNFR1, sTNFR2 and IL-10 was performed as described
previously [9]. IL-1Ra was also measured as described
previously [11] The IL-6 assay was undertaken essen-
tially as in Emsley et al. [12], but instead using PeliPair
anti-IL-6 antibodies (M9316, Sanquin, Amsterdam, the
Netherlands) and development with Zymed steptavidin-
horseradish peroxidise conjugate (ZyMax grade, Zymed
Laboratories, San Francisco, CA, USA). IL-8 was mea-
sured similarly, but using BioSource CytosetTM anti-
bodies and streptavidin (Cat. No. CHC1304; BioSource,
Nivelles, Belgium). All cytokines were standardised in
the laboratory against the latest respective national or
international standards (National Institute for Biological
Standards and Control, South Mimms, UK).
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Statistical analysis
Following log transformation, Pearson’s correlation was
used to calculate the relationship between peripheral
and central IL-6 or IL-8. To identify the relationship be-
tween IL-6 concentration and infection, comparison was
made between either cases defined as having definite
evidence for infection and those with no evidence, or be-
tween those with definite or probable evidence for infec-
tion and those with no evidence or unlikely infection.
Logistic regression was undertaken, both for trend with
increasing peak IL-6 values and in respect of a threshold
IL-6 concentration, chosen from initial inspection of the
data, to determine the odds ratio for association between
IL-6 and infection. Since absence of high CSF IL-6 per-
fectly predicted absence of infection, logistic regression




Twenty-five patients were recruited to the study. The
median age was 53 years (range, 36 to 72 years) and 14
(56%) were women. The aneurysm was anterior circula-
tion in 20 and posterior circulation in four, <10 mm in
20 and, 10 to 25 mm in four (missing data from one).
Sixteen patients underwent coiling, three clipping, one
clipping after failed coiling, and four were treated con-
servatively (missing data from one). The Fisher grade
was 3 in 14 and 4 in 11. The WFNS grade was I in 6, II
in 11, III in 2, IV in 1 and V in 5. The median number
of days from ictus to first sample collection was 2 (range,
0 to 10 days). Matched plasma and CSF samples for at
least three time points were available from 21 patients.
Cytokines and receptors that were similar, or higher, in
plasma compared to CSF
Concentrations of TNF-α were detectable in <30% of CSF
samples and <10% of plasma samples (<0.6 pg/mL; not
shown). Concentrations of IL-1ß in plasma were >2 pg/mL
in only two samples from a single patient. Although 15
CSF samples had concentrations greater than this, and
three samples contained between 10 and 40 pg/mL, the
mean concentrations were similar to those of plasma
(Figure 1). The IL-1 and TNF receptor concentrations,
particularly in CSF, were remarkably similar between
individuals, as indicated by the relatively small interquar-
tile range. The pattern for IL-1Ra was similar to IL-1ß,
although the concentrations were approximately two
orders of magnitude higher. A similar pattern was seen
with TNFR1 and IL-10, although IL-10 was consistently
slightly higher in CSF. For TNFR2 the plasma concen-
trations were approximately three-fold higher than in
CSF and for IL-1R2 the plasma concentrations were
about an order of magnitude higher than in CSF.
High CSF IL-6 and IL-8 concentrations compared to
plasma
The IL-6 and IL-8 concentrations in CSF were between
one and three orders of magnitude higher than in
plasma (Figure 2). In most (97%) paired samples, IL-8
IL-1ß




























































































Figure 1 The median (IQR) values for cytokines and cytokine receptors in paired plasma and CSF samples from 21 patients. All time
points were not available for all patients but are as identified in Figures 3 and 4.
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CSF samples remained an order of magnitude greater
than plasma (Figure 3). There were very different ratios
of plasma and CSF IL-8 between individuals. Correla-
tions for individuals ranged from −0.51 to 0.99, with a
mean of 0.26.
Although plasma and CSF patterns for IL-6 were re-
markably similar to IL-8 in most cases, the order of
magnitude difference in concentrations between CSF
and plasma was maintained in slightly fewer (88%) of
the paired samples (Figure 4) and plasma IL-6 concen-
trations less consistently tracked those in CSF. Correla-
tions for individuals ranged from −0.96 to 0.90, with a
mean of −0.18.
Association between IL-6 and infection
When patients with definite VRI were compared to
those with no evidence of VRI (Table 1), the test for in-
creasing odds with increasing IL-6 was incalculable as
prediction was perfect. Concentrations of IL-6 in CSF
>10,000 pg/mL were significantly associated with VRI
(Fisher’s: P <0.001). When cases of probable VRI were
combined with definite VRI, and cases of unlikely infec-
tion were combined with those having no evidence of
VRI, the test for trend was also significant (P = 0.04).
The association with high IL-6 concentration remained
strongly significant (Fisher’s: P <0.001). When peripheral
infection (Table 1) was analysed in a similar way, with a
cutoff for IL-6 at 30 pg/mL, the odds ratio was not
significant for any of the analyses.
Discussion
Clinical studies of the role of inflammation in brain tissue
rely on determinations of biomarkers from clinically
accessible fluid compartments. Plasma is clearly the
most accessible and can be measured repeatedly to de-
termine changes over time. We have shown that the
concentrations of many of the commonly measured
markers were similar in plasma and CSF compartments
and in some instances plasma markers were higher.
Direct comparisons with studies reported previously
are problematical, since the assays differ and virtually
none make reference to recognised standards. CSF
IL-1ß has been reported as undetectable, or low and
stable, in some studies of SAH [3,13], while another
study reported it as increased, but in the low picogram
range [4], and two others recorded tens to hundreds
of picograms per millilitre [5,6]. TNF-α has similarly
been found to be low or undetectable in some studies
[4,13], but increased in others [6,14]. As in our study,
IL-1Ra and TNFR1 concentrations have been reported
as similar in CSF and plasma or serum, but with an
increase after SAH in at least some patients [14,15].
In contrast, CSF concentrations of IL-6 and IL-8 were
several orders of magnitude greater than those in plasma
after SAH. Other studies have consistently found that
CSF concentrations of IL-6 and IL-8 are increased one
or two orders of magnitude above those in normal CSF
(taken preoperatively for spinal anaesthesia, during elect-
ive aneurysm clipping or for diagnostic purposes that
subsequently found no inflammatory cause) or plasma
values [3,4,6,13,16,17]. There was a superficially steady
relationship between plasma and CSF concentrations for
individual patients, particularly for IL-8. However, the
relationship between these compartments in different
individuals varies considerably, as indicated by the poor
correlation between compartment values for the cohort.
This could reflect variability between individuals in the
transport of cytokines from CSF to plasma, or simply be
due to production occurring discretely in each compart-
ment. The probability of the latter explanation being
correct is suggested by the dissociation between plasma
and CSF IL-6 following infection.
The absence of a gradient concentration between CSF
and plasma for most markers, and the lack of a clear re-
lationship between IL-6 or IL-8 in CSF and plasma, sug-
gest that plasma concentrations of inflammatory
markers cannot provide useful information about in-
flammation in the brain. Several neurosurgical studies
have used microdialysis to address this issue, including a
study in patients with SAH [18,19]. However, apart from
IL-6



































Figure 2 The median (IQR) values for IL-6 and IL-8 in paired plasma and CSF samples from 21 patients. All time points were not available
for all patients but are as identified in Figures 3 and 4.
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Figure 3 Paired plasma and CSF samples from 21 patients were analysed for IL-8 at the times indicated.
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Figure 4 Paired plasma and CSF samples from 21 patients were analysed for IL-6 at the times indicated.
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the difficulty of placing the dialysis probes such that they
provide a representative sample of events taking place in
damaged tissue, collected data may reflect tissue damage
caused by inserting the probes. It is notable that in a
study where a significant change was seen over the col-
lection period (for IL-6, IL-8, macrophage inflammatory
protein 1ß and fibroblast growth factor 2) the highest
values were observed in the first 6 h following probe
insertion and these values fell over the next 24 h [19].
It may be that systemic inflammation and plasma mar-
kers are of greater significance than markers detected in
the CNS, perhaps because this reflects neurovascular in-
volvement. This is borne out to some extent by the
reported associations between systemic inflammation or
peripheral inflammatory markers and clinical outcome
in situations following brain damage [7,20-23].
Our observations additionally raised questions as to
what might be causing some of the changes in cytokine
concentration within compartments and altering the
relationship between central and peripheral concentra-
tions, particularly for IL-6. After reviewing the clinical
report forms and patient notes the most consistent
other event occurring post-EVD insertion was infection.
It is noteworthy that rather little mention is made of
infection in study reports or commentaries on the as-
sociation between cytokines or inflammation following
SAH. Infection is a classic activator of inflammation
and immunity, and bacterial products are widely used
to activate inflammatory responses in experimental set-
tings [24-27]. Ignoring the impact that infection may
have on measures of inflammation seems surprising in
any study of inflammatory markers, but perhaps particu-
larly in conditions where infection is prevalent. Quite
apart from its potential to induce production of cyto-
kines, infection could modify cytokine production occur-
ring as a result of the underlying pathology or might
independently have an important influence on clinical
outcome. Infection therefore has the potential to obscure
relationships between a clinical condition and inflamma-
tion, or to suggest associations where both outcome and
inflammatory markers are independently influenced by
infection.
Depending upon the assessment measures used, in-
fection could potentially alter clinical outcome in sev-
eral ways. It may influence outcome by directly
affecting body systems not threatened by the under-
lying clinical condition of interest, or modify metabolic
functions, including vascular or renal function, such
that the primary pathology progresses more rapidly. Al-
ternatively, the infectious stimulus may exacerbate in-
flammatory responses associated with the condition
being investigated. In this respect, several studies have
shown that infectious stimuli increase the severity of
CNS ischaemic pathology attributable to inflammation
[28,29].
Since each of the measured markers has been asso-
ciated with inflammation it might be expected that most
would be similarly affected by infection. Considering the
remarkably similar production pattern of IL-6 and IL-8
in these SAH patients, it is perhaps particularly surprising
that IL-8 production was quite resistant to modification
by infection. Induction of IL-6 seemed particularly sensi-
tive to infection in the patients studied and these data
suggest that monitoring IL-6 might be used as a marker
of infection.
The association between IL-6 and peripheral infection
has been well described ([25-27,30,31] and has been
indicated as of value in diagnosis [32-34]. It is important
to note that ours was a post-hoc analysis, driven by
observed data, and therefore likely to overstate the asso-
ciation. Nevertheless, the strength of association is strik-
ing and merits further confirmatory studies. Elsewhere,
CSF cytokines have been evaluated to diagnose infection
in a variety of neurosurgical conditions and IL-1 and
TNF were suggested to be of use, whereas IL-6 and IL-8
were not [35]. This contrasts with our study, where IL-1
or TNF were barely detectable and only IL-6 production
was consistently modified by infection.
At least three other studies have considered the value
of monitoring CSF IL-6 to aid the diagnosis of VRI. Of
these, measurement of CSF in four pre-term infants with
hydrocephalus suggested that it may be useful [36]. Ana-
lysis of IL-6 in 21 adult patients with EVDs concluded
that IL-6 was not of value [37]. However, a subsequent
study in 75 patients with EVDs concluded that IL-6 had
Table 1 Association between high CSF IL-6 and CSF
infection
CNS infection CSF IL-6
High (>10,000 pg/mL) Low (<10,000 pg/mL)
Definite i, k, t, u, x, y
Probable w
No m a, b, c, d, h, j, n, o, p, q, s, v
Unlikely ra
aNo CSF taken for culture. Patient letters correspond to those in Figures 3
and 4.
Table 2 Association between high plasma IL-6 and
peripheral infection
Peripheral infection Plasma IL-6
High (>30 pg/mL) Low (<30 pg/mL)
Definite b, c, i, j, m, n, r, w s, t, u, v
Probable k
No p, x h, q
Unlikely y a,d,oa
aPatient letters correspond to those in Figures 3 and 4.
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significant value for predicting VRI 1 day before other
diagnostic markers [38].
The apparent lack of consensus on how VRI is diag-
nosed highlights the need for an improved method for
discrimination. Even positive culture is not definitive
and may be identified as due to catheter colonisation or
contamination in the majority of cases [39]. Similarly,
lack of consensus on use of prophylactic antibiotic cover
during use of intracranial monitors and EVDs [40], com-
bined with current concern over inappropriate use of
antibiotics, identifies the need for improved, early identi-
fication of infection. This study suggests that there
would be value in clarifying whether rapid IL-6 measure-
ment may provide a sufficiently sensitive and specific
marker to identify VRI early and make a better informed
decision on antibiotic use.
Conclusions
The minor differences between some CSF and plasma
cytokines and receptors we identified, combined with
the relatively short half-lives of plasma cytokines, do not
support the concept that plasma markers are primarily
derived from the brain. Further, in the case of cytokines
such as IL-6 and IL-8, where there is a significant differ-
ence in CSF and plasma concentrations, and these differ-
ences are relatively stable within individuals, the
variability of the difference between individuals means
that it is not possible to deduce differences in CSF
concentrations from those observed in plasma. Infection
has an important influence on cytokine production, par-
ticularly in the case of IL-6. The data suggest that ac-
count should be taken of infection in patients where
inflammatory markers are being evaluated and that IL-6
may be a valuable early indicator of CSF infection in
patients with EVDs.
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